Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering ivps42020-06-29T07:14:01-04:00 Read More
Achieve Announces Successful Results from the Investigator-Initiated RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix (varenicline) as a Treatment to Quit Smoking ivps42020-06-29T07:14:32-04:00 Read More
Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program ivps42020-05-13T16:50:34-04:00 Read More
Achieve Life Sciences to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 14, 2020 ivps42020-05-04T15:22:00-04:00 Read More
Achieve Life Sciences Announces Private Placement of $1.9 Million ivps42020-04-30T15:51:08-04:00 Read More
Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program ivps42020-03-11T16:19:12-04:00 Read More
Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting ivps42020-03-11T12:52:47-04:00 Read More
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2019 Financial Results and Host Conference Call and Webcast on March 13, 2020 ivps42020-03-02T16:11:51-04:00 Read More
Achieve Life Sciences Announces Agreement with the FreeMind Group to Assist in Securing Non-Dilutive Funding to Evaluate Cytisinicline in Vaping and e-Cigarette Users ivps42020-02-05T14:45:03-04:00 Read More
Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug Discovery ivps42020-01-13T12:17:22-04:00 Read More
